JP2023501038A - 新規の治療的使用 - Google Patents

新規の治療的使用 Download PDF

Info

Publication number
JP2023501038A
JP2023501038A JP2022507857A JP2022507857A JP2023501038A JP 2023501038 A JP2023501038 A JP 2023501038A JP 2022507857 A JP2022507857 A JP 2022507857A JP 2022507857 A JP2022507857 A JP 2022507857A JP 2023501038 A JP2023501038 A JP 2023501038A
Authority
JP
Japan
Prior art keywords
cells
inhibitor
pol
compound
deficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2022507857A
Other languages
English (en)
Japanese (ja)
Inventor
マリー ルース ロビンソン ヘレン
キャメロン ムレイ スミス グラエメ
ジェームズ ロード クリストファー
ザトレアヌ ダイアナ
Original Assignee
アルティオス ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルティオス ファーマ リミテッド filed Critical アルティオス ファーマ リミテッド
Publication of JP2023501038A publication Critical patent/JP2023501038A/ja
Priority to JP2024012755A priority Critical patent/JP2024059632A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022507857A 2019-08-09 2019-08-09 新規の治療的使用 Ceased JP2023501038A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024012755A JP2024059632A (ja) 2019-08-09 2024-01-31 新規の治療的使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2019/052243 WO2021028644A1 (en) 2019-08-09 2019-08-09 Novel therapeutic use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024012755A Division JP2024059632A (ja) 2019-08-09 2024-01-31 新規の治療的使用

Publications (1)

Publication Number Publication Date
JP2023501038A true JP2023501038A (ja) 2023-01-18

Family

ID=74570294

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022507857A Ceased JP2023501038A (ja) 2019-08-09 2019-08-09 新規の治療的使用
JP2024012755A Pending JP2024059632A (ja) 2019-08-09 2024-01-31 新規の治療的使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024012755A Pending JP2024059632A (ja) 2019-08-09 2024-01-31 新規の治療的使用

Country Status (6)

Country Link
US (1) US20220387544A1 (https=)
EP (1) EP4010002A1 (https=)
JP (2) JP2023501038A (https=)
CN (1) CN114728036A (https=)
CA (1) CA3149112A1 (https=)
WO (1) WO2021028644A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12358886B2 (en) * 2019-08-09 2025-07-15 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer
EP4455129A4 (en) * 2021-12-30 2025-05-07 Shanghai Apeiron Therapeutics Company Limited Dna polymerase theta inhibitor and use thereof
TW202332442A (zh) 2022-01-31 2023-08-16 瑞士商瑞森製藥公司 ＰＯＬθ抑制劑
WO2024197653A1 (en) * 2023-03-29 2024-10-03 Suzhou Eoc Medical Research Co., Ltd. Heterocyclic compounds and uses thereof
WO2025011603A1 (zh) * 2023-07-12 2025-01-16 南京再明医药有限公司 一种化合物用于预防或治疗53BP1/Shieldin复合物缺陷的癌症的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070198A1 (en) * 2015-10-19 2017-04-27 Dana-Farber Cancer Institute, Inc. Polymerase q as a target in hr-deficient cancers
WO2021028643A1 (en) * 2019-08-09 2021-02-18 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013133876A1 (en) * 2011-12-07 2013-09-12 The Regents Of The University Of California Biomarkers for prediction of response to parp inhibition in breast cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070198A1 (en) * 2015-10-19 2017-04-27 Dana-Farber Cancer Institute, Inc. Polymerase q as a target in hr-deficient cancers
WO2021028643A1 (en) * 2019-08-09 2021-02-18 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
NATURE, vol. vol.560, issue 7716, JPN6023024591, 2018, pages 122 - 127, ISSN: 0005087842 *
NATURE, vol. vol.560, issue 7716, JPN6023024593, 2018, pages 112 - 116, ISSN: 0005087840 *
NATURE, vol. vol.560, issue 7716, JPN6023024594, 2018, pages 117 - 121, ISSN: 0005087841 *
SCIENCE, vol. vol.359, issue 6381, JPN6023024592, 2018, pages 1217 - 1218, ISSN: 0005201618 *

Also Published As

Publication number Publication date
WO2021028644A1 (en) 2021-02-18
CA3149112A1 (en) 2021-02-18
US20220387544A1 (en) 2022-12-08
CN114728036A (zh) 2022-07-08
EP4010002A1 (en) 2022-06-15
JP2024059632A (ja) 2024-05-01

Similar Documents

Publication Publication Date Title
AU2019416117B2 (en) CSF1R inhibitors for use in treating cancer
TWI843127B (zh) 二醯基甘油激酶調節化合物
EP4010329B1 (en) Deuterated compounds for use in the treatment of cancer
JP2024059632A (ja) 新規の治療的使用
TWI843126B (zh) 二醯基甘油激酶調節化合物
US11999733B2 (en) Diacylglycerol kinase modulating compounds
ES2986019T3 (es) Tratamientos contra el cáncer que usan combinaciones de inhibidores de ERK y MEK de tipo 2
TWI854244B (zh) 二醯基甘油激酶調節化合物
US20240166623A1 (en) Novel process
KR20240122783A (ko) Fgfr 저해제 및 kras 저해제를 포함하는 병용 요법
TW202334150A (zh) 新穎化合物
WO2021178789A1 (en) Methods of using rebastinib in the treatment of different cancerous disorders
CN118632696A (zh) 包含fgfr抑制剂和kras抑制剂的组合疗法
HK40076656B (en) Deuterated compounds for use in the treatment of cancer
HK40076656A (en) Deuterated compounds for use in the treatment of cancer
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物
HK40082507A (en) Diacylglycerol kinase modulating compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230919

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240131

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240305

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240430

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20240827